Cencora — Nov 6, 2024 release

Since the Company’s preliminary fiscal 2025 guidance provided on its Form 8-K filed on September 5, 2024, Cencora has executed on opportunistic share repurchases in September and October and had continued momentum in the business. The Company expects: • Revenue growth to be in the range of 7 to 9 percent; ◦ U.S. Healthcare Solutions segment revenue growth to be in the range of 7 to 9 percent; ◦ International Healthcare Solutions segment revenue growth to be in the range of 7 to 9 percent; • Adjusted diluted earnings per share to be in the range of $14.80 to $15.10.     Additional expectations include: • Adjusted operating income growth to be in the range of 5 to 6.5 percent; ◦ U.S. Healthcare Solutions segment operating income growth to be in the range of 5 to 6.5 percent; ◦ International Healthcare Solutions segment operating income growth to be in the range of 5 to 6.5 percent; • Interest expense to be in the range of $150 million to $170 million; • Adjusted effective tax rate of approximately 21 percent; • Adjusted free cash flow to be in the range of $2.0 billion to $3.0 billion; • Capital expenditures to be approximately $600 million; and • Weighted average diluted shares outstanding to be approximately 196 million. Cencora’s fiscal 2025 guidance does not currently include the impact of the RCA acquisition, which will be incorporated into expectations following the transaction close. For additional details regarding guidance expectations on a constant currency basis, please r